More patients achieved composite reductions of $\geq 1\%$ HbA_{1c}, $\geq 5\%$ body weight and ≥ 5 mmHg systolic blood pressure with semaglutide versus comparators (SUSTAIN 1–5, 7)

Gowri Subramanian¹; Kathleen Dungan²; Vanita R Aroda³; Filip K Knop⁴; Lawrence A Leiter⁵; Nanna L Lausvig⁶; Søren Lindberg⁶; Juris Meier⁷ ¹Novo Nordisk Ltd., Gatwick, UK; ²The Ohio State University, Columbus, OH, USA; ³MedStar Health Research Institute, Hyattsville, MD, USA; ⁴Center for Diabetes Research, Gentofte Hospital, University of Copenhagen, Hellerup, Denmark; ⁵Li Ka Shing Knowledge Institute, St. Michael's Hospital, University of Toronto, ON, Canada; ⁶Novo Nordisk A/S, Søborg, Denmark; ⁷Diabetes Division, St. Josef Hospital, Ruhr-University Bochum, Bochum, Germany

Aim

- Cardiovascular (CV) disease is the leading cause of death among people with type 2 diabetes (T2D),¹ and treatments that reduce the risk of CV events in patients with T2D are warranted.
- Modification of CV risk factors is important for long-term CV risk management in patients with T2D.²
- Semaglutide (Novo Nordisk, Denmark) is a glucagon-like peptide-1 (GLP-1) analogue for the treatment of T2D.^{3,4}
- SUSTAIN (Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes) is a global, phase 3 clinical trial programme designed to evaluate the efficacy and safety of once-weekly subcutaneous semaglutide.^{5–11}
- Across the SUSTAIN trial programme, subjects with T2D achieved greater reductions in two or three of the CV risk factors: HbA_{1c}, body weight (BW) and systolic blood pressure (SBP), with semaglutide vs placebo or active comparators.⁵⁻¹¹
 Decreases of HbA_{1c} ≥1%, BW ≥5% and SBP ≥5 mmHg are generally considered to be clinically meaningful.¹²⁻¹⁴
 This *post hoc* analysis evaluated to what extent subjects across the SUSTAIN trials 1–5 and 7 achieved clinically meaningful reductions in the composite of these three CV risk factors with semaglutide vs placebo or active comparators.

Figure 1: Proportion of subjects achieving the composite endpoint of ≥1% decrease in HbA_{1c}, ≥5% BW loss and ≥5 mmHg SBP reduction in the SUSTAIN 1–5 and 7 trials

	SUSTAIN 1 (vs placebo)	SUSTAIN 2 (vs sitagliptin)	SUSTAIN 3 (vs exenatide ER)	SUSTAIN 4 (vs IGlar)	SUSTAIN 5 (vs placebo)	SUSTAIN 7 (vs dulaglutide)
Background:	N/A	Add-on to MET, TZD, MET/TZD	Add-on to 1–2 OADs	Add-on to MET, MET/SU	Add-on to basal insulin ± MET	Add-on to MET
Treatment duration (weeks):	30	56	56	30	30	40
n:	128 130 129	409 409 407	404 405	362 360 360	132 131 133	301 299 300 299
50		1				
б 45 •		1				
. 40 ·					*	

Methods

SUSTAIN 1–5 and 7 trial designs

In SUSTAIN 1–5 and 7, adults with T2D (HbA_{1c} 7.0–10.0% for SUSTAIN 1, 4 and 5, and 7.0–10.5% for SUSTAIN 2, 3 and 7) were randomised to receive semaglutide 0.5 mg, semaglutide 1.0 mg or comparators (placebo, sitagliptin, exenatide extended release [ER], insulin glargine and dulaglutide) for 30, 40 or 56 weeks.^{5–9,11}


Statistical analysis

- In this *post hoc* analysis, the composite endpoint (≥1% decrease in HbA_{1c}, ≥5% BW loss and ≥5 mmHg SBP reduction) was analysed using a logistic regression model with:
- » Treatment, trial-specific stratification and country as fixed factors.
- » Baseline values for individual components as covariates.
- Missing values for each component were imputed using a mixed model for repeated measurements.

Results

Baseline characteristics and demographics


Baseline measurements were broadly consistent across SUSTAIN 1–5 and 7, with mean baseline HbA_{1c}, BW and SBP values ranging from 8.1–8.4%, 89.5–95.8 kg and 128.8–134.8 mmHg, respectively (Table 1).




*p<0.001 for semaglutide (0.5 mg or 1.0 mg) vs comparator. Comparison for SUSTAIN 7 is semaglutide 0.5 mg vs dulaglutide 0.75 mg and semaglutide 1.0 mg vs dulaglutide 1.5 mg. 'On-treatment without rescue medication' data are presented. Logistic regression with treatment, trial-specific stratification and country as fixed factors, and baseline HbA_{1c}, BW and SBP as covariate. Missing values for each component were imputed using a mixed model for repeated measurements with trial-specific stratification and country as fixed factors, and baseline value as covariate, all nested within visit. BW, body weight; exenatide ER, exenatide extended release; IGIar, insulin glargine; MET, metformin; N/A, not applicable; OAD, oral antidiabetic drug; SBP, systolic blood pressure; SU, sulphonylurea; TZD, thiazolidinedione

Figure 2: Proportion of subjects achieving the composite endpoint (≥1% decrease in HbA_{1c}, ≥5% BW loss and ≥5 mmHg SBP reduction) at each scheduled visit over the duration of each trial: (A) SUSTAIN 1, (B) SUSTAIN 2, (C) SUSTAIN 3, (D) SUSTAIN 4, (E) SUSTAIN 5 and (F) SUSTAIN 7

(A) SUSTAIN 1 (vs placebo)



(D) SUSTAIN 4 (vs IGlar)



— Semaglutide 1.0 mg

— IGlar

Key result

Composite endpoint analyses

- Significantly more subjects achieved the composite endpoint with semaglutide (0.5 mg: 14–20%; 1.0 mg: 15–37%) than with placebo (2%) or active comparators (1–12%); p<0.001 for all comparisons (Figure 1).
- Evaluation of the two trials with GLP-1 receptor agonists (GLP-1RAs) as comparators showed that the composite endpoint was achieved by a significantly greater proportion of subjects treated with semaglutide (0.5 mg: 19%; 1.0 mg: 22–33%) vs exenatide ER (2.0 mg: 6%; SUSTAIN 3) or dulaglutide (0.75 mg: 7%; 1.5 mg: 12%; SUSTAIN 7); p<0.001 for all comparisons (Figure 1).
- A greater proportion of subjects achieved the composite endpoint at an early timepoint in the trials with semaglutide than with placebo or the active comparators, with differences being observed as early as week 8 (semaglutide vs placebo or insulin glargine) and week 12 (semaglutide vs sitagliptin, exenatide ER or dulaglutide) (Figure 2).

 Table 1: Baseline characteristics and demographics


SUSTAIN 1⁵ (vs placebo)	SUSTAIN 2 ⁶ (vs sitagliptin)	(vs	SUSTAIN 4 ⁸ (vs IGlar)	(vs	SUSTAIN 7 ¹¹ (vs dulaglutide)
Mono- therapy	Add-on to MET, TZD, MET/TZD	Add-on to 1–2 OADs	Add-on to MET, MET/ SU	Add-on to basal insulin ± MET	Add-on to MET
30 weeks	56 weeks	56 weeks	30 weeks	30 weeks	40 weeks

Subject disposition, N (%)

	Randomised	388	1,231	813	1,089	397	1,201
--	------------	-----	-------	-----	-------	-----	-------


— Semaglutide 0.5 mg — Semaglutide 1.0 mg — Placebo

(B) SUSTAIN 2 (vs sitagliptin)




- Semagiutide 0.5 mg - Semagiutide 1.0 mg - Sitagiiptin 100






(E) SUSTAIN 5 (vs placebo)

- Semaglutide 0.5 mg



— Semaglutide 0.5 mg — Semaglutide 1.0 mg —

(F) SUSTAIN 7 (vs dulaglutide)



'On-treatment without rescue medication' data are presented. A mixed model for repeated measurements imputation was used for missing data. BW, body weight; exenatide ER, exenatide extended release; IGlar, insulin glargine; SBP, systolic blood pressure

- The biggest treatment difference for the individual components with the specified cutoffs (≥1% decrease in HbA_{1c}, ≥5% BW loss and ≥5 mmHg SBP reduction) was seen for HbA_{1c} and BW (data not shown).
- Semaglutide was associated with CV benefits in the SUSTAIN 6 trial, in which subjects with T2D and at high CV risk were treated with semaglutide or placebo.¹⁰

Exposed	387 (99.7)	1,225 (99.5)	809 (99.5)	1,082 (99.4)	396 (99.7)	1,199 (99.8)		
Baseline characteristics, mean (SD)								
Age, years	53.7 (11.3)	55.1 (10.0)	56.6 (10.7)	56.5 (10.4)	58.8 (10.1)	56.0 (10.6)		
Diabetes duration, years	4.2 (5.5)	6.6 (5.1)	9.2 (6.3)	8.6 (6.3)	13.3 (7.8)	7.4 (5.7)		
HbA _{1c} , %	8.1 (0.9)	8.1 (0.9)	8.3 (1.0)	8.2 (0.9)	8.4 (0.8)	8.2 (0.9)		
Body weight, kg	91.9 (23.8)	89.5 (20.3)	95.8 (21.5)	93.5 (21.8)	91.7 (21.0)	95.2 (22.6)		
SBP, mmHg	128.8 (13.2)	132.6 (14.9)	133.5 (14.5)	132.1 (15.3)	134.8 (16.0)	133.0 (14.3)		

- Similar results were observed when altering the cutoffs in the triple composite endpoints (data not shown):
- » HbA_{1c} <7% (absolute value), ≥5% BW loss and ≥5 mmHg SBP reduction.
- » ≥1% decrease in HbA_{1c}, ≥3% BW loss and ≥3 mmHg SBP reduction.

Discussion

- In this post hoc analysis across the SUSTAIN 1–5 and 7 trials, more subjects achieved the composite endpoint (≥1% decrease in HbA_{1c}, ≥5% weight loss and ≥5 mmHg SBP reduction) with semaglutide than with placebo or active comparators (p<0.001 for all).
- For the GLP-1RAs exenatide ER and dulaglutide, the difference between the treatments observed at the last visit was established from week 16 onwards (Figure 2: C and F).
- » The rate of CV death, non-fatal myocardial infarction or non-fatal stroke was significantly lower among subjects receiving semaglutide than among those receiving placebo (hazard ratio, 0.74, 95% confidence interval, 0.58–0.95; p<0.001 for non-inferiority, p=0.02 for superiority).¹⁰

Conclusion

- A higher proportion of subjects receiving semaglutide achieved the composite endpoint compared with placebo and comparators used in clinical practice (insulin glargine, dipeptidyl peptidase-4 inhibitors, GLP-1RAs).
- These clinically meaningful improvements in CV risk factors, including improvements in glycaemia, BW loss and SBP reduction, may contribute to a decrease in long-term CV complications in patients with T2D.

The SUSTAIN studies were sponsored by Novo Nordisk and registered with ClinicalTrials.gov (NCT02054897, NCT01930188, NCT01885208, NCT02128932, NCT02305381 and NCT02648204). Gowri Subramanian is presenting on behalf of the authors. Presenter Gowri Subramanian is an employee of Novo Nordisk. The authors are grateful to Stacy Carl-McGrath, PhD, AXON Communications (supported by Novo Nordisk) for writing assistance. First presented at the 54th Annual Meeting of the European Association for the Study of Diabetes (EASD), 1–5 October 2018, Berlin, Germany. Presented at the Autumn Meeting of the Association of British Clinical Diabetologists (ABCD). 8–9 November 2018, London, UK. **References:** (1) The Emerging Risk Factors Collaboration. Lancet 2010;375:2215–22. (2) American Diabetes Association. Diabetes Care 2016;39(Suppl 1):S60–71. (3) Lau J et al. J Med Chem 2015;58:7370–80. (4) Novo Nordisk. Ozempic[®] (semaglutide) Prescribing Information. Available at: http://www.novo-pi.com/ozempic.pdf. Accessed June 2018. (5) Sorli C et al. Lancet Diabetes Endocrinol 2017;5:251–60. (6) Ahrén B et al. Lancet Diabetes Endocrinol 2017;5:341–54. (7) Ahmann AJ et al. Diabetes Care 2018;41:258–66. (8) Aroda VR et al. Lancet Diabetes Endocrinol 2017;5:355–66. (9) Rodbard HW et al. J Clin Endocrinol Metab 2018;103:2291–301. (10) Marso SP et al. N Engl J Med 2016;375: 1834–44. (11) Pratley RE et al. Lancet Diabetes Endocrinol 2018;6:275–86. (12) Stratton IM et al. BMJ 2000;321:405–12. (13) Jensen MD et al. Obesity (Silver Spring) 2014; 22(Suppl 2):S5–39. (14) Turnbull F et al. Lancet 2003;362:1527–35.